-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team On September 29, 2021, Expansion Therapeutics announced the completion of a US$80 million Series B financing
.
The funds will be used to advance the small molecule drug platform (SMiRNA) targeting RNA to discover the treatment of myotonic muscular dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and more A drug candidate for tauopathies
.
A ribonuclease targeted chimera (RIBOTAC) technology developed by the company’s scientific founders can achieve targeted degradation of specific RNA
.
Expansion focuses on patients with neurological diseases that have few treatment options, such as DM1, a systemic disease that affects muscle, heart, and brain functions
.
Expansion focuses on RNA targets that are evolutionarily conserved or genetically proven to cause diseases and have three-dimensional structures
.
Expansion combines patient genetics with in-depth informatics analysis to identify those RNA structures that can bind to ligands, and then uses RNA-specific small molecule libraries to screen out small molecules that regulate the function of RNA targets
.
Subsequently, its new structural biology SMiRNA platform will be used to design and advance lead compounds, and ultimately provide an oral drug for the treatment of diseases
.
Expansion has also recently received licenses for two new research projects at the Scripps Institute, including a project for tau protein
.
Tau protein is an important driver of dementia
.
Studies have found that the abnormal mRNA precursor encoding tau protein is involved in the formation of neurofibrillary tangles and is associated with tau protein diseases (such as Alzheimer’s disease, frontotemporal dementia, progressive supranuclear palsy) and other neurodegenerative diseases Related
.
Image source: Expansion Therapeutics President and CEO Dr.
Renato Skerlj said: “Small molecule drugs targeting RNA are expected to greatly change the lives of patients and treat serious RNA-mediated diseases, including neurodegenerative diseases and neurological diseases.
.
this financing milestone demonstrates investors' use of our proprietary technology platform to accelerate clinical confidence before new drugs and clinical development
.
"references: [1] Expansion Therapeutics Raises $ 80 Million Series B financing to Treat Neurodegenerative Diseases Retrieved September.
29, 2021, from https:// Disclaimer: Medicine The content team of Mingkangde focuses on introducing the global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
.
The funds will be used to advance the small molecule drug platform (SMiRNA) targeting RNA to discover the treatment of myotonic muscular dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and more A drug candidate for tauopathies
.
A ribonuclease targeted chimera (RIBOTAC) technology developed by the company’s scientific founders can achieve targeted degradation of specific RNA
.
Expansion focuses on patients with neurological diseases that have few treatment options, such as DM1, a systemic disease that affects muscle, heart, and brain functions
.
Expansion focuses on RNA targets that are evolutionarily conserved or genetically proven to cause diseases and have three-dimensional structures
.
Expansion combines patient genetics with in-depth informatics analysis to identify those RNA structures that can bind to ligands, and then uses RNA-specific small molecule libraries to screen out small molecules that regulate the function of RNA targets
.
Subsequently, its new structural biology SMiRNA platform will be used to design and advance lead compounds, and ultimately provide an oral drug for the treatment of diseases
.
Expansion has also recently received licenses for two new research projects at the Scripps Institute, including a project for tau protein
.
Tau protein is an important driver of dementia
.
Studies have found that the abnormal mRNA precursor encoding tau protein is involved in the formation of neurofibrillary tangles and is associated with tau protein diseases (such as Alzheimer’s disease, frontotemporal dementia, progressive supranuclear palsy) and other neurodegenerative diseases Related
.
Image source: Expansion Therapeutics President and CEO Dr.
Renato Skerlj said: “Small molecule drugs targeting RNA are expected to greatly change the lives of patients and treat serious RNA-mediated diseases, including neurodegenerative diseases and neurological diseases.
.
this financing milestone demonstrates investors' use of our proprietary technology platform to accelerate clinical confidence before new drugs and clinical development
.
"references: [1] Expansion Therapeutics Raises $ 80 Million Series B financing to Treat Neurodegenerative Diseases Retrieved September.
29, 2021, from https:// Disclaimer: Medicine The content team of Mingkangde focuses on introducing the global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
